Tirzepatide: History and Approval
Tirzepatide went from an unnamed laboratory compound to one of the most prescribed metabolic medicines in less than ten years. Its story shows how quickly a drug can move when early results are strong, and how many separate trials regulators still expect before approving each use.
The Idea of Combining Incretins
The first GLP-1 medicine, exenatide, reached the market in 2005. Around 2010, research groups began to design single peptides that activate more than one metabolic receptor, hoping to add effects that one hormone could not reach alone. Lilly chose to build its candidate on the GIP sequence and to tune it so it also activated the GLP-1 receptor.
Discovery and First Human Studies
Lilly researchers described LY3298176 in Molecular Metabolism in 2018. The paper combined cell and mouse experiments with the first human trials, in which 142 people received tirzepatide, dulaglutide or placebo. In obese mice, tirzepatide reduced food intake and body weight more than a GLP-1 agonist alone. In people, the drug's profile supported weekly dosing, and the main side effects were gastrointestinal.
Phase 2: A Signal That Changed Plans
A 26-week Phase 2 trial in 318 people with type 2 diabetes was published in The Lancet in 2018. At the highest dose, HbA1c fell by 1.94 percentage points, against 1.21 points with dulaglutide, and weight loss was also greater. These results led Lilly to launch two large Phase 3 programmes at the same time.
SURPASS and SURMOUNT
SURPASS, which began in 2019, tested tirzepatide in type 2 diabetes against placebo, semaglutide, insulin degludec and insulin glargine. SURMOUNT tested it for chronic weight management in people with obesity or overweight. The first SURPASS papers appeared in 2021, and SURMOUNT-1 was published in the New England Journal of Medicine in 2022.
Approvals
- May 2022: the US Food and Drug Administration (FDA) approved tirzepatide as Mounjaro for adults with type 2 diabetes.
- September 2022: the European Commission granted an EU-wide marketing authorisation for Mounjaro in type 2 diabetes, following a positive opinion from the European Medicines Agency (EMA). The authorisation was later extended to weight management.
- November 2023: the FDA approved tirzepatide as Zepbound for chronic weight management.
- December 2024: the FDA approved Zepbound for moderate to severe obstructive sleep apnoea in adults with obesity, based on the SURMOUNT-OSA trials.
Studies Since Approval
Research has continued well beyond the original uses. Trials published in 2024 and 2025 looked at sleep apnoea, heart failure with preserved ejection fraction, liver disease (MASH), prevention of type 2 diabetes, and a direct comparison with semaglutide. SURPASS-CVOT, a trial in more than 13,000 people with type 2 diabetes and heart disease, was published in December 2025. It compared cardiovascular outcomes with those of dulaglutide, an older GLP-1 medicine.
Looking Ahead
Each new use still has to be approved separately by regulators, and the approved uses differ between the EU, the UK and the US. Studies of long-term outcomes, other conditions and different patient groups are ongoing.